胸腺瘤术后辅助放疗的现状及进展

doi:10.3760/cma.j.cn113030-20190614-00012

Abstract
Figure/Table
References(47)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Surgical resection is the most important treatment of thymoma. However,the role of postoperative adjuvant radiotherapy (PORT) has been controversial. The survival benefits of two-dimensional radiotherapy are not significant. However,precision radiotherapy has significantly changed tumor radiotherapy. The value of PORT for thymoma may also be altered. At present,the effect of radiotherapy in patients with positive surgical margins or inoperable resection is confirmed. For patients with complete surgical resection,Masaoka-Koga stage Ⅰ patients do not require PORT. Whether PORT should be given for stage Ⅱ patients remains debated if stage Ⅱ b, large volume and B2/B3 type were considered during radiotherapy. The role of PORT for stage Ⅲ patients is also in disputed, whereas a majority of findings support the application of PORT. Precision technology is recommended during PORT.The clinical target volume suggests that the three-dimensional expansion of the tumor bed is 0.5 cm, including the mediastinal pleura involved by the tumor and 0.5-1.0 cm along the anterior and posterior direction of the mediastinal pleura, the cranial and caudal direction, the lung side is expanded within the 0.5 cm, and the vascular wall around the tumor and part of the vascular space, so as to avoid including too much normal tissue.The dose for complete resection is 45-50 Gy and 54-60 Gy or slightly higher for incomplete resection,which may increase the benefits and reduce the risk of PORT.The application of new radiotherapy techniques such as particle therapy can gain the advantage of dosimetric distribution, and whether it can be transformed into clinical benefits needs to be further explored.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zeng Qiang
	Zhai Yirui
	Wang Xiaodan
	Feng Qinfu

Key words： Thymoma/radiotherapy Radiotherapy postoperative Progress

Received: 14 June 2019

Fund:National Key Research and Development Program (2016YFC0904600); Fundamental Research Funds for the Central Universities (3332018075)

Corresponding Authors: Feng Qinfu,Email:qinfufeng19@163.com

Cite this article:

Zeng Qiang,Zhai Yirui,Wang Xiaodan et al. Current situation and research progress on postoperative adjuvant radiotherapy for thymoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(4): 308-312.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190614-00012 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I4/308

[1] Engels EA. Epidemiology of thymoma and associated malignancies[J]. J Thorac Oncol,2010,5(10 Suppl 4):S260-265. DOI:10.1097/JTO.0b013e3181f1f6d.
[2] Siesling S,van der Zwan JM,Izarzugaza I,et al. Rare thoracic cancers,including peritoneum mesothelioma[J]. Eur J Cancer,2012,48(7):949-960. DOI:10.1016/j.ejca.2012.02.047.
[3] Fang W,Fu J,Shen Y,et al. Management of thymic tumors-consensus based on the Chinese Alliance for Research in Thymomas Multi-institutional retrospective studies[J]. J Thorac Dis,2016,8(4):641-645. DOI:10.21037/jtd.2016.03.23.
[4] Lu CF,Yu L,Jing Y,et al. Value of Adjuvant Radiotherapy for Thymoma with Myasthenia Gravis after Extended Thymectomy[J]. Chin Med J (Engl),2018,131(8):927-932. DOI:10.4103/0366-6999.229894.
[5] Phillips LH. The epidemiology of myasthenia gravis[J]. Semin Neurol,2004,24(1):17-20. DOI:10.1055/s-2004-829593.
[6] Lee GD,Kim HR,Choi SH,et al. Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems[J]. J Thorac Dis,2016,8(5):901-910. DOI:10.21037/jtd.2016.03.53.
[7] Marchevsky AM,Gupta R,Casadio C,et al. World Health Organization classification of thymomas provides significant prognostic information for selected stage Ⅲ patients:evidence from an international thymoma study group[J]. Hum Pathol,2010,41(10):1413-1421. DOI:10.1016/j.humpath.2010.02.012.
[8] Masaoka A,Monden Y,Nakahara K,et al. Follow-up study of thymomas with special reference to their clinical stages[J]. Cancer,1981,48(11):2485-2492. DOI:10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r.
[9] Koga K,Matsuno Y,Noguchi M,et al. A review of 79 thymomas:modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma[J]. Pathol Int,1994,44(5):359-367. DOI:10.1111/j.1440-1827.1994.tb02936.x.
[10] 刘乾文,谷志涛,杨富,等. 术后放疗在Ⅰ期/Ⅱ期/Ⅲ期胸腺肿瘤中的作用—ChART回顾性数据库研究结果[J]. 中国肺癌杂志,2016,19(7):465-472. DOI:10.3779/j.issn.1009-3419.2016.07.09.
Liu QW,Gu ZT,Yang F,et al. Role of postoperative radiotherapy for Stage Ⅰ/Ⅱ/Ⅲ thymic tumor-results of the ChART retrospective database[J]. Chin J Lung Cancer,2016,19(7):465-472. DOI:10.3779/j.issn.1009-3419.2016.07.09.
[11] Detterbeck FC. Evaluation and treatment of stage Ⅰ and Ⅱ thymoma[J]. J Thorac Oncol,2010,5(10 Suppl 4):S318-322. DOI:10.1097/JTO.0b013e3181f20dab.
[12] Fan C,Feng Q,Chen Y,et al. Postoperative radiotherapy for completely resected Masaoka stage Ⅲ thymoma:a retrospective study of 65 cases from a single institution[J]. Radiat Oncol,2013,8:199. DOI:10.1186/1748-717X-8-199.
[13] Chen YD,Feng QF,Lu HZ,et al. Role of adjuvant radiotherapy for stage Ⅱ thymoma after complete tumor resection[J]. Int J Radiat Oncol Biol Phys,2010,78(5):1400-1406. DOI:10.1016/j.ijrobp.2009.09.066.
[14] Kondo K,Monden Y. Therapy for thymic epithelial tumors:a clinical study of 1,320 patients from Japan[J]. Ann Thorac Surg,2003,76(3):878-884;discussion 884-885. DOI:10.1097/JTO.0b013e3182745f73.
[15] Harnath T,Marx A,Strobel P,et al. Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose[J]. J Thorac Oncol,2012,7(12):1867-1871. DOI:10.1097/JTO.0b013e3182745f73.
[16] Jackson MW,Palma DA,Camidge DR,et al. The impact of postoperative radiotherapy for thymoma and thymic carcinoma[J]. J Thorac Oncol,2017,12(4):734-744. DOI:10.1016/j.jtho.2017.01.002.
[17] Rimner A,Gomez DR,Wu AJ,et al. Failure patterns relative to radiation treatment fields for stage Ⅱ-Ⅳ thymoma[J]. J Thorac Oncol,2014,9(3):403-409. DOI:10.1097/JTO.0000000000000099.
[18] Xu C,Feng QF,Fan CC,et al. Patterns and predictors of recurrence after radical resection of thymoma[J]. Radiother Oncol,2015,115(1):30-34. DOI:10.1016/j.radonc.2015.03.001.
[19] 张红星,汪楣,谷铣之.Ⅰ期胸腺瘤的前瞻性临床治疗研究[J]. 中华放射肿瘤学杂志,1998,7(4):218-221. DOI:10.3760/j.issn:1004-4221.1998.04.005.
Zhang HX,Wang M,Gu XZ. Postoperative radiotherapy for stage Ⅰ thymoma:A prospective randomized trial on 29 cases[J]. Chin J Radiat Oncol,1998,7(4):218-221. DOI:10.3760/j.issn:1004-4221.1998.04.005.
[20] Rena O,Papalia E,Oliaro A,et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage Ⅱ thymoma?[J]. Eur J Cardiothorac Surg,2007,31(1):109-113. DOI:10.1016/j.ejcts.2006.10.022.
[21] Chang JH,Kim HJ,Wu HG,et al. Postoperative radiotherapy for completely resected stage Ⅱ or Ⅲ thymoma[J]. J Thorac Oncol,2011,6(7):1282-1286. DOI:10.1097/JTO.0b013e31821f9662.
[22] Omasa M,Date H,Sozu T,et al. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage Ⅱ and Ⅲ thymic epithelial tumors:the Japanese Association for Research on the Thymus Database Study[J]. Cancer,2015,121(7):1008-1016. DOI:10.1002/cncr.29166.
[23] Mangi AA,Wright CD,Allan JS,et al. Adjuvant radiation therapy for stage Ⅱ thymoma[J]. Ann Thorac Surg,2002,74(4):1033-1037. DOI:10.1016/s0003-4975(02)03828-6.
[24] Singhal S,Shrager JB,Rosenthal DI,et al. Comparison of stages I-Ⅱ thymoma treated by complete resection with or without adjuvant radiation[J]. Ann Thorac Surg,2003,76(5):1635-1641. DOI:10.1016/s0003-4975(03)00819-1.
[25] Berman AT,Litzky L,Livolsi V,et al. Adjuvant radiotherapy for completely resected stage 2 thymoma[J]. Cancer,2011,117(15):3502-3508. DOI:10.1002/cncr.25851.
[26] Lim YJ,Kim E,Kim HJ,et al. Survival impact of adjuvant radiation therapy in Masaoka Stage Ⅱ to Ⅳ thymomas:a systematic review and Meta-analysis[J]. Int J Radiat Oncol Biol Phys,2016,94(5):1129-1136. DOI:10.1016/j.ijrobp.2016.01.007.
[27] Zhou D,Deng XF,Liu QX,et al. The effectiveness of postoperative radiotherapy in patients with completely resected thymoma:a Meta-analysis[J]. Ann Thorac Surg,2016,101(1):305-310. DOI:10.1016/j.athoracsur.2015.06.034.
[28] Rimner A,Yao X,Huang J,et al. Postoperative radiation therapy is associated with longer overall survival in completely resected Stage Ⅱ and Ⅲ thymoma-an analysis of the International Thymic Malignancies Interest Group Retrospective Database[J]. J Thorac Oncol,2016,11(10):1785-1792. DOI:10.1016/j.jtho.2016.06.011.
[29] Liao J,Liu T,Zhang H,et al. The role of postoperative radiation therapy for completely resected stage Ⅲ thymoma and effect of higher heart radiation dose on risk of cardiovascular disease:a retrospective cohort study[J]. Int J Surg,2018,53:345-349. DOI:10.1016/j.ijsu.2018.04.018.
[30] Lim YJ,Kim HJ,Wu HG. Role of Postoperative radiotherapy in nonlocalized thymoma:propensity-matched analysis of surveillance,epidemiology,and end results database[J]. J Thorac Oncol,2015,10(9):1357-1363. DOI:10.1097/JTO.0000000000000619.
[31] Rena O,Mineo TC,Casadio C. Multimodal treatment for stage ⅠVA thymoma:a proposable strategy[J]. Lung Cancer,2012,76(1):89-92. DOI:10.1016/j.lungcan.2011.10.004.
[32] Huang J,Rizk NP,Travis WD,et al. Feasibility of multimodality therapy including extended resections in stage ⅠVA thymoma[J]. J Thorac Cardiovasc Surg,2007,134(6):1477-1483;discussion 1483-1484. DOI:10.1016/j.jtcvs.2007.07.049.
[33] Ciernik IF,Meier U,Lutolf UM. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy[J]. J Clin Oncol,1994,12(7):1484-1490. DOI:10.1200/JCO.1994.12.7.1484.
[34] Curran WJ Jr,Kornstein MJ,Brooks JJ,et al. Invasive thymoma:the role of mediastinal irradiation following complete or incomplete surgical resection[J]. J Clin Oncol,1988,6(11):1722-1727. DOI:10.1200/JCO.1988.6.11.1722.
[35] Venuta F,Rendina EA,Longo F,et al. Long-term outcome after multimodality treatment for stage Ⅲ thymic tumors[J]. Ann Thorac Surg,2003,76(6):1866-1872;discussion 1872. DOI:10.1016/s0003-4975(03)01020-8.
[36] Leuzzi G,Rocco G,Ruffini E,et al. Multimodality therapy for locally advanced thymomas:a propensity score-matched cohort study from the European Society of Thoracic Surgeons Database[J]. J Thorac Cardiovasc Surg,2016,151(1):47-57. DOI:10.1016/j.jtcvs.2015.08.034.
[37] Kondo K,Monden Y. Lymphogenous and hematogenous metastasis of thymic epithelial tumors[J]. Ann Thorac Surg,2003,76(6):1859-1864. DOI:10.1016/s0003-4975(03)01017-8.
[38] Ogawa K,Uno T,Toita T,et al. Postoperative radiotherapy for patients with completely resected thymoma:a multi-institutional,retrospective review of 103 patients[J]. Cancer,2002,94(5):1405-1413. DOI:10.1002/cncr.10373.
[39] Sugie C,Shibamoto Y,Ikeya-Hashizume C,et al. Invasive thymoma:postoperative mediastinal irradiation,and low-dose entire hemithorax irradiation in patients with pleural dissemination[J]. J Thorac Oncol,2008,3(1):75-81. DOI:10.1097/JTO.0b013e31815e8b73.
[40] Zhu G,He S,Fu X,et al. Radiotherapy and prognostic factors for thymoma:a retrospective study of 175 patients[J]. Int J Radiat Oncol Biol Phys,2004,60(4):1113-1119. DOI:10.1016/j.ijrobp.2004.05.013.
[41] Eng TY,Thomas CR Jr. Radiation therapy in the management of thymic tumors[J]. Semin Thorac Cardiovasc Surg,2005,17(1):32-40. DOI:10.1053/j.semtcvs.2004.12.005.
[42] Mornex F,Resbeut M,Richaud P,et al. Radiotherapy and chemotherapy for invasive thymomas:a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer[J]. Int J Radiat Oncol Biol Phys,1995,32(3):651-659. DOI:10.1016/0360-3016(95)00079-E.
[43] Haefner MF,Verma V,Bougatf N,et al. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma[J]. Acta Oncol,2018,57(12):1713-1720. DOI:10.1080/0284186X.2018.1502467.
[44] Parikh RR,Rhome R,Hug E,et al. Adjuvant proton beam therapy in the management of thymoma:a dosimetric comparison and acute toxicities[J]. Clin Lung Cancer,2016,17(5):362-366. DOI:10.1016/j.cllc.2016.05.019.
[45] Vogel J,Lin L,Litzky LA,et al. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma[J]. Int J Radiat Oncol Biol Phys,2017,99(2):427-433. DOI:10.1016/j.ijrobp.2017.04.022.
[46] Mou H,Liao Q,Hou X,et al. Clinical characteristics,risk factors,and outcomes after adjuvant radiotherapy for patients with thymoma in the United States:analysis of the surveillance,epidemiology,and end results (SEER) registry (1988-2013)[J]. Int J Radiat Biol,2018,94(5):495-502. DOI:10.1080/09553002.2018.1454618.
[47] Fernandes AT,Shinohara ET,Guo M,et al. The role of radiation therapy in malignant thymoma:a surveillance,epidemiology,and end results database analysis[J]. J Thorac Oncol,2010,5(9):1454-1460. DOI:10.1097/JTO.0b013e3181e8f345.